HRP20180804T1 - Inhibitori dnk-pk - Google Patents
Inhibitori dnk-pk Download PDFInfo
- Publication number
- HRP20180804T1 HRP20180804T1 HRP20180804TT HRP20180804T HRP20180804T1 HR P20180804 T1 HRP20180804 T1 HR P20180804T1 HR P20180804T T HRP20180804T T HR P20180804TT HR P20180804 T HRP20180804 T HR P20180804T HR P20180804 T1 HRP20180804 T1 HR P20180804T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- compound
- acceptable salt
- cancer
- pharmaceutical composition
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/056,560 US9376448B2 (en) | 2012-04-24 | 2013-10-17 | DNA-PK inhibitors |
| EP14800181.1A EP3057959B1 (en) | 2013-10-17 | 2014-10-17 | Dna-pk inhibitors |
| PCT/US2014/061033 WO2015058031A1 (en) | 2013-10-17 | 2014-10-17 | Dna-pk inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180804T1 true HRP20180804T1 (hr) | 2018-08-10 |
Family
ID=51932571
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180804TT HRP20180804T1 (hr) | 2013-10-17 | 2014-10-17 | Inhibitori dnk-pk |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP3057959B1 (enExample) |
| JP (1) | JP6374959B2 (enExample) |
| CN (1) | CN105636958B (enExample) |
| AU (1) | AU2014337208B2 (enExample) |
| BR (1) | BR112016008423B1 (enExample) |
| CA (1) | CA2927392C (enExample) |
| DK (1) | DK3057959T3 (enExample) |
| ES (1) | ES2671354T3 (enExample) |
| HR (1) | HRP20180804T1 (enExample) |
| HU (1) | HUE037516T2 (enExample) |
| LT (1) | LT3057959T (enExample) |
| PL (1) | PL3057959T3 (enExample) |
| PT (1) | PT3057959T (enExample) |
| RS (1) | RS57306B1 (enExample) |
| SI (1) | SI3057959T1 (enExample) |
| TR (1) | TR201807411T4 (enExample) |
| WO (1) | WO2015058031A1 (enExample) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI633087B (zh) | 2012-06-13 | 2018-08-21 | 赫孚孟拉羅股份公司 | 新穎二氮雜螺環烷及氮雜螺環烷 |
| EP3590940B1 (en) | 2012-09-25 | 2021-06-09 | F. Hoffmann-La Roche AG | Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| NO3074400T3 (enExample) | 2013-11-26 | 2018-04-14 | ||
| MA39792B1 (fr) | 2014-03-26 | 2019-12-31 | Hoffmann La Roche | Composés bicycliques en tant qu'inhibiteurs de production d'autotaxine (atx) et d'acide lysophosphatidique (lpa) |
| EP3122751B1 (en) | 2014-03-26 | 2019-10-30 | F.Hoffmann-La Roche Ag | Condensed [1,4]diazepine compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| MX387736B (es) | 2015-09-04 | 2025-03-18 | Hoffmann La Roche | Derivados de fenoximetilo. |
| MX2017015034A (es) | 2015-09-24 | 2018-04-13 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores duales de autotaxina (atx)/anhidrasa carbonica (ca). |
| PE20180451A1 (es) | 2015-09-24 | 2018-03-05 | Hoffmann La Roche | Nuevos compuestos biciclicos como inhibidores de atx |
| CN107635995B (zh) | 2015-09-24 | 2022-08-19 | 豪夫迈·罗氏有限公司 | 作为atx抑制剂的二环化合物 |
| KR20180054634A (ko) | 2015-09-24 | 2018-05-24 | 에프. 호프만-라 로슈 아게 | 이중 오토탁신(atx)/탄산 무수화효소(ca) 억제제로서 신규한 이환형 화합물 |
| CR20180323A (es) | 2015-11-20 | 2018-08-06 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituídos como moduladores de los receptores de pge2 |
| JP2019529475A (ja) | 2016-09-27 | 2019-10-17 | バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ | Ｄｎａ損傷剤とｄｎａ−ｐｋ阻害剤との組合せ物を使用する、がんを処置するための方法 |
| CN110382484B (zh) | 2017-03-16 | 2022-12-06 | 豪夫迈·罗氏有限公司 | 新的作为atx抑制剂的二环化合物 |
| MA49879A (fr) | 2017-03-16 | 2020-06-24 | Hoffmann La Roche | Composés hétérocycliques utiles en tant qu'inhibiteurs doubles d'atx/ca |
| CN110612296A (zh) | 2017-05-18 | 2019-12-24 | 爱杜西亚药品有限公司 | 作为pge2受体调节剂的苯基衍生物 |
| MX394108B (es) | 2017-05-18 | 2025-03-21 | Idorsia Pharmaceuticals Ltd | Derivados de indol n-sustituidos. |
| JP7093791B2 (ja) | 2017-05-18 | 2022-06-30 | イドーシア ファーマシューティカルズ リミテッド | Ｐｇｅ２レセプター調節剤としてのベンゾフラン及びベンゾチオフェン誘導体 |
| AU2018268311B2 (en) | 2017-05-18 | 2022-02-10 | Idorsia Pharmaceuticals Ltd | Pyrimidine derivatives as PGE2 receptor modulators |
| TW201900180A (zh) * | 2017-05-18 | 2019-01-01 | 瑞士商愛杜西亞製藥有限公司 | 嘧啶衍生物 |
| WO2019100062A1 (en) | 2017-11-20 | 2019-05-23 | Ichan School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CN111819193A (zh) | 2018-01-05 | 2020-10-23 | 西奈山伊坎医学院 | 增加胰腺β细胞增殖的方法、治疗方法以及组合物 |
| AU2019209292B2 (en) | 2018-01-17 | 2023-10-05 | Vertex Pharmaceuticals Incorporated | Quinoxalinone compounds, compositions, methods, and kits for increasing genome editing efficiency |
| BR112020014140A2 (pt) | 2018-01-17 | 2020-12-01 | Vertex Pharmaceuticals Incorporated | inibidores de dna-pk |
| AU2019240065A1 (en) | 2018-03-20 | 2020-09-24 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| EP3906028A4 (en) * | 2018-12-31 | 2022-10-12 | Icahn School of Medicine at Mount Sinai | KINA INHIBITOR COMPOUNDS AND COMPOSITIONS AND METHODS OF USE |
| CN112300126A (zh) * | 2019-07-31 | 2021-02-02 | 山东轩竹医药科技有限公司 | 杂环类dna-pk抑制剂 |
| CN112574179B (zh) * | 2019-09-29 | 2022-05-10 | 山东轩竹医药科技有限公司 | Dna-pk抑制剂 |
| CN112574211B (zh) * | 2019-09-29 | 2022-06-14 | 山东轩竹医药科技有限公司 | 杂环类激酶抑制剂 |
| EP4086258A4 (en) * | 2019-12-31 | 2023-11-29 | Chengdu Baiyu Pharmaceutical Co., Ltd. | PURINE DERIVATIVE AND ITS MEDICAL USE |
| CN121712509A (zh) | 2023-05-04 | 2026-03-20 | 锐新医药公司 | 用于ras相关疾病或病症的组合疗法 |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| IL327306A (en) | 2023-10-12 | 2026-05-01 | Revolution Medicines Inc | Macrocyclic RAS inhibitors |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025217307A1 (en) | 2024-04-09 | 2025-10-16 | Revolution Medicines, Inc. | Methods for predicting response to a ras(on) inhibitor and combination therapies |
| WO2025229177A1 (en) | 2024-05-02 | 2025-11-06 | Idorsia Pharmaceuticals Ltd | Crystalline forms of an n-substituted indole derivative |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026050446A1 (en) | 2024-08-29 | 2026-03-05 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026072904A2 (en) | 2024-09-26 | 2026-04-02 | Revolution Medicines, Inc. | Compositions and methods for treating lung cancer |
| WO2026090116A2 (en) | 2024-10-21 | 2026-04-30 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026090245A1 (en) | 2024-10-22 | 2026-04-30 | Revolution Medicines, Inc. | Use of ras inhibitors for treating cancer |
| US20260108528A1 (en) | 2024-10-22 | 2026-04-23 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1351946A2 (en) * | 2000-09-01 | 2003-10-15 | Icos Corporation | Materials and methods to potentiate cancer treatment |
| EP1678147B1 (en) * | 2003-09-15 | 2012-08-08 | Lead Discovery Center GmbH | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| JP2008542219A (ja) * | 2005-05-25 | 2008-11-27 | インゲニウム ファーマシューティカルズ ジーエムビーエイチ | 疼痛処置法 |
| MX2009003456A (es) * | 2006-10-02 | 2009-04-14 | Irm Llc | Compuestos y composiciones como inhibidores de proteina cinasa. |
| US8518948B2 (en) * | 2010-03-10 | 2013-08-27 | Ingenium Pharmaceuticals Gmbh | Inhibitors of protein kinases |
| SI3459942T1 (sl) * | 2012-04-24 | 2021-05-31 | Vertex Pharmaceuticals Incorporated | Inhibitorji DNA-PK |
-
2014
- 2014-10-17 SI SI201430733T patent/SI3057959T1/en unknown
- 2014-10-17 HR HRP20180804TT patent/HRP20180804T1/hr unknown
- 2014-10-17 HU HUE14800181A patent/HUE037516T2/hu unknown
- 2014-10-17 DK DK14800181.1T patent/DK3057959T3/en active
- 2014-10-17 ES ES14800181.1T patent/ES2671354T3/es active Active
- 2014-10-17 TR TR2018/07411T patent/TR201807411T4/tr unknown
- 2014-10-17 PL PL14800181T patent/PL3057959T3/pl unknown
- 2014-10-17 WO PCT/US2014/061033 patent/WO2015058031A1/en not_active Ceased
- 2014-10-17 BR BR112016008423-3A patent/BR112016008423B1/pt active IP Right Grant
- 2014-10-17 EP EP14800181.1A patent/EP3057959B1/en active Active
- 2014-10-17 CN CN201480057118.6A patent/CN105636958B/zh active Active
- 2014-10-17 RS RS20180605A patent/RS57306B1/sr unknown
- 2014-10-17 PT PT148001811T patent/PT3057959T/pt unknown
- 2014-10-17 JP JP2016523925A patent/JP6374959B2/ja active Active
- 2014-10-17 AU AU2014337208A patent/AU2014337208B2/en active Active
- 2014-10-17 CA CA2927392A patent/CA2927392C/en active Active
- 2014-10-17 LT LTEP14800181.1T patent/LT3057959T/lt unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS57306B1 (sr) | 2018-08-31 |
| SI3057959T1 (en) | 2018-07-31 |
| ES2671354T3 (es) | 2018-06-06 |
| CA2927392C (en) | 2021-11-09 |
| DK3057959T3 (en) | 2018-06-06 |
| CN105636958A (zh) | 2016-06-01 |
| EP3057959B1 (en) | 2018-02-28 |
| CA2927392A1 (en) | 2015-04-23 |
| BR112016008423A2 (enExample) | 2017-08-01 |
| LT3057959T (lt) | 2018-06-11 |
| AU2014337208B2 (en) | 2018-05-24 |
| WO2015058031A1 (en) | 2015-04-23 |
| PL3057959T3 (pl) | 2018-08-31 |
| CN105636958B (zh) | 2018-01-05 |
| HUE037516T2 (hu) | 2018-09-28 |
| JP2016533366A (ja) | 2016-10-27 |
| EP3057959A1 (en) | 2016-08-24 |
| JP6374959B2 (ja) | 2018-08-15 |
| BR112016008423B1 (pt) | 2022-02-22 |
| TR201807411T4 (tr) | 2018-06-21 |
| PT3057959T (pt) | 2018-06-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI3057959T1 (en) | DNA-PK INHIBITORS | |
| JP2016533366A5 (enExample) | ||
| BR112015008365A2 (pt) | composto da fórmula b-l(d)x, ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso de um composto, composição de forma de dosagem unitária ou dose unitária, composição para tratar um câncer em um paciente, e método para tratar um câncer em um paciente | |
| PH12018501807A1 (en) | Pyrazolopyrrolidine derivatives and their use in the treatment of diseas | |
| HRP20250250T1 (hr) | Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji | |
| MX2015016421A (es) | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades. | |
| EA201591363A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| CO6680717A2 (es) | Derivados de quinolina y quinoxalina como inhibidores de cinasa | |
| MX2016005394A (es) | Compuestos derivados de piridilo biciclicos fusionados a anillo como inhibidores de fgfr4. | |
| SA515360469B1 (ar) | مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها | |
| TR201819653T4 (tr) | Karaciğer kanserinin tedavisinde kullanılmaya yönelik organik bileşik. | |
| BR112015021549A2 (pt) | inibidores de piridina cinase cdk9 | |
| AR092661A1 (es) | Inhibidor de quinasas reordenadas durante la transfeccion (ret) y un metodo para identificar un paciente sensible a un compuesto representado por la formula (1) | |
| HRP20250119T1 (hr) | Kdm1a inhibitor i njegova primjena u terapiji | |
| EA201491671A1 (ru) | Гетероциклильные соединения | |
| HRP20190537T1 (hr) | Farmaceutske kombinacije koje sadrže inhibitor b-raf, inhibitor egfr i po izboru inhibitor pi3k-alfa | |
| TN2016000017A1 (en) | Piperidinyl indole derivatives and their use as complement factor b inhibitors | |
| MX2015016425A (es) | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades. | |
| EA201201658A1 (ru) | Производные пиперидина и их применение для лечения метаболических нарушений | |
| PT3069720T (pt) | Composição farmacológica que contém derivados de glutarimida, e a aplicação da mesma no tratamento de doenças eosinofílicas | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| HRP20200662T1 (hr) | Ljekoviti pripravak koji sadrži spoj diamino heterocikličkog karboksamida kao aktivni sastojak | |
| CY1122387T1 (el) | Διπλης χρησης δισκια στοματικης φαρμακευτικης συνθεσης θειικων αλατων και μεθοδοι χρησης αυτων | |
| IL269710A (en) | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers | |
| MX369952B (es) | Derivados de 1,4-dihidrodioxina fusionada como inhibidores del factor de transcripción de choque térmico 1. |